These subtle effects of UHRF1 downmodulation on RB cell proliferation and viability suggested that UHRF1 targeting alone may not be efficacious for RB treatment, and subsequently led to exploration for therapeutic applications in combination with other agents. Here, RB1 is linked to retinoblastoma.